Breast cancer is a condition marked by the unchecked proliferation of malignant cells in the breast tissue. Breast cancer treatments are medicines used to treat breast cancer. These medications are made to target and block the development of cancer cells, reduce tumor size, and stop the spread of cancer to other body regions. In addition to this, a number of additional treatment options are also available, including radiation therapy, chemotherapy, and hormone therapy. The key factor fueling the market expansion is the growing prevalence of breast cancer and related issues among the population. Increasing usage of hormone therapy in breast cancer treatment is driving the market growth. In addition, the increasing development in the field of targeted therapy for breast cancer will open up more business potential for the market.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-breast-cancer-drug-market
Data Bridge Market Research analyzes that the Global Breast Cancer Drugs Market is expected to reach USD 55,996.57 million by 2030 from USD 30,247.54 million in 2022, growing at a CAGR of 8.2% during the forecast period of 2023 to 2030.
Key Findings of the Study
Advancements in drugs associated with breast cancer treatment
Innovation in drug development has been a transformative force in the global breast cancer drugs market, driving advancements in treatment options and significantly improving patient outcomes. Breast cancer is one of the most prevalent and deadly cancers globally, making it a key focus area for pharmaceutical research and development. The continuous evolution of therapies and treatment approaches has enhanced the quality of care, thus propelling market growth.
One of the most notable innovations in breast cancer drug development is the advent of targeted therapies. These drugs are designed to specifically target the molecular and genetic characteristics of the tumor of an individual, resulting in more precise and effective treatment. The development of drugs such as Herceptin, which targets the HER2 protein, and CDK4/6 inhibitors such as Palbociclib, have revolutionized the management of breast cancer, leading to significantly improved survival rates and reduced side effects. In addition, immunotherapy has also emerged as a groundbreaking innovation, with drugs such as Pembrolizumab and Atezolizumab showing efficiency in strengthening the body's immune system to combat breast cancer. Moreover, the field of precision medicine, guided by genetic profiling and biomarker identification, enables tailored treatment strategies. These innovations provide new hope for patients and contribute to the remarkable market expansion as demand for these life-saving therapies continues to rise. Thus, the continuous innovation in drug development in breast cancer treatment, offering new avenues for improved patient outcomes and a brighter future in the fight against this devastating disease, is driving the market growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Year
|
2021 (Customizable 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Product Type (Medication, Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), Cancer Type (Invasive Ductal Carcinoma (IDC), Invasive Lobular Carcinoma (ILC), Inflammatory Breast Cancer, Paget’s Disease of the Nipple, Angiosarcoma of the Breast, Phyllodes Tumors of the Breast, Non-Invasive (In-situ) Types of Breast Cancer, Ductal Carcinoma In Situ (DCIS), Lobular Carcinoma In Situ (LCIS), Metastatic Breast Cancer, and Others), Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), Drug Type (Generic and Branded), Age Group (Geriatric and Adults), Route of Administration (Oral and Intravenous), End User (Hospitals, Specialty Clinics, Cancer Centers, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, and Rest of Middle East and Africa
|
|
Market Players Covered
|
Novartis AG (Switzerland), Pfizer Inc. (U.S.), Viatris Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Eli Lilly and Company (U.S.), F. Hoffman- La Roche Ltd. (Switzerland), Sanofi (France), AstraZeneca (U.K.), Teva Pharmaceutical Industries Ltd (Israel), Eisai Co., Ltd. (Japan), Kyowa Kirin Co., Ltd (Japan), Merck & Co., Inc (U.S.), Gilead Sciences, Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), AbbVie, Inc. (U.S.), and MacroGenics, Inc. (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The global breast cancer drugs market is segmented into eight notable segments based on product type, cancer type, stages, drug type, age group, route of administration, end user, and distribution channel.
- On the basis of product type, the market is segmented into medication, chemotherapy, targeted therapy, radiation therapy, and others
In 2023, the medication segment of the product type segment is expected to dominate the market
In 2023, the medication segment is expected to dominate the market with a market share of 31.84% due to the rising prevalence of breast cancer among the population.
- On the basis of cancer type, the market is segmented into Invasive Ductal Carcinoma (IDC), Invasive Lobular Carcinoma (ILC), inflammatory breast cancer, paget’s disease of the nipple, angiosarcoma of the breast, phyllodes tumors of the breast, non-invasive (In-situ) types of breast cancer, Ductal Carcinoma In Situ (DCIS), Lobular Carcinoma In Situ (LCIS), metastatic breast cancer, and others
In 2023, the Invasive Ductal Carcinoma (IDC) segment of the gene type segment is expected to dominate the market
In 2023, the Invasive Ductal Carcinoma (IDC) segment is expected to dominate the market with a market share of 71.89% due to the changes in lifestyle habits.
- On the basis of stages, the market is segmented into stage 0, stage I, stage II, stage III, and stage IV
- On the basis of drug type, the market is segmented into generic and branded. In 2023, the branded segment is expected to dominate the market with a market share of 67.83%
- On the basis of age group, the market is segmented into geriatric and adults. In 2023, the geriatrics segment is expected to dominate the market with a market share of 84.02%
- On the basis of route of administration, the market is segmented into oral and intravenous. In 2023, the intravenous segment is expected to dominate the market with a market share of 68.14%
- On the basis of end user, the market is segmented into hospitals, specialty clinics, cancer centers, and others. In 2023, the hospitals segment is expected to dominate the market with a market share of 35.75%
- On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. In 2023, the hospital pharmacy segment is expected to dominate the market with a market share of 46.57%
Major Players
Data Bridge Market Research analyzes F. Hoffman- La Roche Ltd. (Switzerland), Pfizer, Inc (U.S.), AstraZeneca (U.K.), Novartis AG (Switzerland), and Eli Lilly and Company (U.S.) as the major players operating in the market.
Market Development
- In September 2023, Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519), a subsidiary of F. Hoffmann-La Roche Ltd, announced that it had obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW), Japan for Phesgo. Phesgo is a fixed-dose combination of pertuzumab and trastuzumab (the monoclonal antibodies contained in Perjeta and Herceptin), which are used in HER2-positive breast cancer. This approval enabled the company to deliver its products to breast cancer patients in broader areas
- In September 2023, AstraZeneca announced that the TROPION-Breast01 Phase III trial reported highly favorable outcomes, indicating that datopotamab deruxtecan (Dato-DXd) displayed a statistically significant and clinically significant enhancement in terms of Progression-Free Survival (PFS) when compared to the choice of chemotherapy made by the investigator. This improvement was observed in patients with inoperable or metastatic breast cancer characterized by hormone receptor (HR)-positive, HER2-low or negative status (IHC 0, IHC 1+ or IHC 2+/ISH-), who had previously undergone endocrine-based therapy and at least one systemic therapy after the completion of successful trials
- In June 2023, Novartis AG presented the pivotal Phase III NATALEE trial's favorable primary endpoint statistics at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2023. Data showed that Kisqali (ribociclib) plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by 25.2% in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (HR=0.748; 95% CI: 0.618, 0.906; p=0.0014) along with a consistent, clinically meaningful invasive disease-free survival (iDFS) benefit across key pre-specified subgroups
- In July 2022, Roche (SIX: RO, ROG; OTCQX: RHHBY) updated data from the phase III APHINITY study in HER2-positive early breast cancer conducted in collaboration with the Breast International Group (BIG), the Institut Jules Bordet Clinical Trials Support Unit (IJB-CTSU), and Frontier Science Foundation (FS). The 8.4 years study showed positive results in the patients who used a combination of Perjeta (pertuzumab), Herceptin (trastuzumab), and chemotherapy (the Perjeta-based regimen) as compared to those patients who used Herceptin, chemotherapy, and placebo. The company officials announced that the results of the study show great progress made in treating the aggressive form of early breast cancer
- In June 2022, Pfizer Inc. (NYSE:PFE) announced the results of the overall survival rate from the phase 3 PALOMA-2 trial of IBRANCE (palbociclib) in combination with letrozole compared to placebo plus letrozole for the first-line treatment of postmenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). IBRANCE continues to provide substantial benefits as a first-line treatment for adults with HR+, HER2- mBC based on strong progression-free survival data, which formed the basis of its worldwide approvals
Regional Analysis
Geographically, the countries covered in the global breast cancer drugs market report are the U.S., Canada, Mexico, France, Germany, Spain, Italy, U.K., Spain, Netherlands, Russia, Turkey, Switzerland, rest of Europe, China, Japan, Thailand, India, South Korea, Australia, Singapore, Indonesia, Philippines, Malaysia, rest of Asia-Pacific, Brazil, Argentina, rest of South America, U.A.E., Saudi Arabia, South Africa, Israel, Egypt, and rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is expected to dominate the market and is the fastest-growing region in the global breast cancer drugs market
North America is expected to dominate the market owing to the higher investments by U.S. manufacturers and service providers and the increasing technological advancement. It will continue to dominate the market in terms of market share and revenue and flourish its dominance during the forecast period. It is expected to grow during the forecast period due to the growing population with the rising prevalence of chronic and complex diseases in this region.
For more detailed information about the global breast cancer drugs market report, click here – https://www.databridgemarketresearch.com/reports/global-breast-cancer-drug-market
